The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Efficacy of anti-myeloma therapies following relapse on idecabtagene vicleucel
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a study evaluating the efficacy of subsequent anti-myeloma therapy in patients with multiple myeloma who relapse after treatment with idecabtagene vicleucel (ide-cel). In this study, 68 patients received different types of treatment after progressing on ide-cel, including corticosteroids, proteasome inhibitors, alkylating agents, immunomodulatory drugs and anti-BCMA therapy. Overall, the time to second disease progression (PFS2) was 13.6 months in patients who received subsequent anti-myeloma treatment and 15.6 months in patients who received anti-BCMA treatment. Overall survival (OS) reached 24.8 months and the overall response to any subsequent treatment was 76% in patients who received subsequent anti-myeloma treatment and 90% in patients who received subsequent anti-BCMA treatment. This data suggests that patients who relapse following treatment with ide-cel still respond to BCMA as a target, and that subsequent anti-myeloma treatments remain effective. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
